Watch the full video on Radcliffe Cardiology: Dr Davide Cao (Icahn School of Medicine at Mount Sinai, US) discusses the key results and impact on clinical practice of the pre-specified analysis of the TWILIGHT trial presented at ESC Congress 2021.
TWILIGHT-HBR evaluated the effects of ticagrelor monotherapy versus ticagrelor (Brilinta) plus aspirin on bleeding and ischemic outcomes in a contemporary ARC-defined HBR population undergoing percutaneous coronary intervention (PCI).
The study showed that selected HBR patients who tolerated 3 months of DAPT with ticagrelor after PCI, withdrawing aspirin and continuing ticagrelor monotherapy for 1 year, significantly decreased clinically relevant as well as major bleeding events without compromising ischemic protection, as compared with ticagrelor plus aspirin.
Questions:
-The importance of TWILIGHT-HBR
-Study design and patient population
-Key results
-mpact on practice and influence on further research
Recorded remotely from New York, 2021.
Interviewer: Jordan Rance
Editor: Mirjam Boros
Radcliffe Cardiology is a dynamic, digitally-focused producer & publisher of Cardiovascular, Renal and Metabolic (CVRM) content for physicians worldwide. We aim to assist in the continuous education of physicians within the cardiology fraternity, generating a range of clinical content through collaboration with leading cardiologists from around the globe.
Музыка
Фильмы
ТВ Шоу
Категории видео
